These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7235987)

  • 21. International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products (VICH); final guidance for industry on "studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing" (VICH GL23); availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jan; 67(3):602-3. PubMed ID: 12358039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A proposed battery of tests for the initial evaluation of the mutagenic potential of medicinal and industrial chemicals.
    Ishidate M
    Mutat Res; 1988; 205(1-4):397-407. PubMed ID: 3367924
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutagenicity screening: general principles and minimal criteria. Report of a committee of the European Environmental Mutagen Society.
    Mutat Res; 1978 Jun; 53(3):361-7. PubMed ID: 353541
    [No Abstract]   [Full Text] [Related]  

  • 24. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization.
    Guth BD; Germeyer S; Kolb W; Markert M
    J Pharmacol Toxicol Methods; 2004; 49(3):159-69. PubMed ID: 15172012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies and testing methods for identifying mutagenic risks.
    MacGregor JT; Casciano D; Müller L
    Mutat Res; 2000 Nov; 455(1-2):3-20. PubMed ID: 11113464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop.
    Kirkland D; Pfuhler S; Tweats D; Aardema M; Corvi R; Darroudi F; Elhajouji A; Glatt H; Hastwell P; Hayashi M; Kasper P; Kirchner S; Lynch A; Marzin D; Maurici D; Meunier JR; Müller L; Nohynek G; Parry J; Parry E; Thybaud V; Tice R; van Benthem J; Vanparys P; White P
    Mutat Res; 2007 Mar; 628(1):31-55. PubMed ID: 17293159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Problems of testing drugs for potential mutagenicity.
    Matter BE
    Mutat Res; 1976 Aug; 38(4):243-58. PubMed ID: 820991
    [No Abstract]   [Full Text] [Related]  

  • 28. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic activation of drugs in mutagenicity tests in vitro.
    Roberfroid MB
    Arch Toxicol; 1980 Nov; 46(1-2):181-93. PubMed ID: 7235994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the Miniscreen assay to screen novel compounds for bacterial mutagenicity in the pharmaceutical industry.
    Burke DA; Wedd DJ; Burlinson B
    Mutagenesis; 1996 Mar; 11(2):201-5. PubMed ID: 8671739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagens.
    Jacobson-Kram D; Contrera JF
    Toxicol Sci; 2007 Mar; 96(1):16-20. PubMed ID: 17194803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project.
    Honma M; Kitazawa A; Cayley A; Williams RV; Barber C; Hanser T; Saiakhov R; Chakravarti S; Myatt GJ; Cross KP; Benfenati E; Raitano G; Mekenyan O; Petkov P; Bossa C; Benigni R; Battistelli CL; Giuliani A; Tcheremenskaia O; DeMeo C; Norinder U; Koga H; Jose C; Jeliazkova N; Kochev N; Paskaleva V; Yang C; Daga PR; Clark RD; Rathman J
    Mutagenesis; 2019 Mar; 34(1):3-16. PubMed ID: 30357358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.
    Galloway SM
    Environ Mol Mutagen; 2017 Jun; 58(5):296-324. PubMed ID: 28299826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An appraisal of mutagenicity test systems.
    Anderson D; Longstaff E
    Analyst; 1981 Jan; 106(1258):1-22. PubMed ID: 7008648
    [No Abstract]   [Full Text] [Related]  

  • 35. Chemical purity and mutagenicity: case study of a drug in development.
    Kropko ML; Jaen JC; Theiss JC; Wold S; Caprathe BW; Wise LD
    Mutat Res; 1992 Apr; 281(4):233-8. PubMed ID: 1373215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of medicinal plant extracts from Chinese herbal medicines on the mutagenic activity of benzo[a]pyrene.
    Sakai Y; Nagase H; Ose Y; Sato T; Kawai M; Mizuno M
    Mutat Res; 1988 Nov; 206(3):327-34. PubMed ID: 3059179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the mutagenic potential of chemicals. The minimal battery and extrapolation problems.
    Sobels FH
    Arch Toxicol; 1980 Nov; 46(1-2):21-30. PubMed ID: 7235996
    [No Abstract]   [Full Text] [Related]  

  • 38. The role of the UKEMS in the development of testing guidelines.
    Kirkland DJ
    Mutagenesis; 2002 Nov; 17(6):451-5. PubMed ID: 12435841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme-mediated mutagenicity in Salmonella typhimurium of contaminants of synthetic indigo products.
    Jongen WM; Alink GM
    Food Chem Toxicol; 1982 Dec; 20(6):917-20. PubMed ID: 6761249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ICH S5(R2) guideline for the testing of medicinal agents.
    Wise LD
    Methods Mol Biol; 2013; 947():1-11. PubMed ID: 23138891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.